In silico study: combination of -mangostin and chitosan conjugated with trastuzumab against human epidermal growth factor receptor 2

HIGHLIGHTS

  • who: Sandra Megantara et al. from the Department of Pharmaceutical Analysis and Medicinal Chemistry, Universitas Padjadjaran, Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, Egypt have published the research work: In Silico Study: Combination of -Mangostin and Chitosan Conjugated with Trastuzumab against Human Epidermal Growth Factor Receptor 2, in the Journal: Polymers 2022, 2747 of 29/06/2022
  • what: The conjugation of the combined particle of α-mangostin and chitosan with trastuzumab was successfully carried out.
  • how: The results indicated that the pArticle of and combinations interacted mostly with the crystallizable fragment (Fc . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?